Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b vaccine + hepatitis b vaccine
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination vaccine is designed to provide active immunization against invasive disease caused by *Haemophilus influenzae* type b (Hib) and infection caused by all known subtypes of the hepatitis B virus (HBV). The Hib component consists of the purified capsular polysaccharide (polyribosylribitol phosphate, PRP) of *H. influenzae* type b, which is covalently linked to an outer membrane protein complex (OMPC) of *Neisseria meningitidis* to enhance immunogenicity in infants. The hepatitis B component contains purified surface antigen (HBsAg) produced by recombinant DNA technology in *Saccharomyces cerevisiae*. By presenting these antigens to the immune system, the vaccine stimulates the production of specific protective antibodies (anti-PRP and anti-HBs). It was primarily indicated for infants born to HBsAg-negative mothers, starting at 6 weeks of age.
- Brand names
- Comvax
- Other names
- Hib-HepB vaccineHaemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on haemophilus influenzae type b vaccine + hepatitis b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b vaccine + hepatitis b vaccine.